Related Experiment Video
Updated: Jun 20, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Head and neck cancer: integrating anti-EGFR treatment with standard therapy
1Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. mkies@mdanderson.org
Abstract:
The combination of chemotherapy and radiation is increasingly considered a standard treatment for patients with locally advanced squamous cell carcinoma of the head and neck. Tumor control is often obtained, but toxicity is increased with combined modality treatment. The efficacy of platinum-based chemotherapy regimens has been well documented. Carboplatin offers a favorable toxicity profile compared with cisplatin. Carboplatin-based regimens have been evaluated for both locally advanced and metastatic or recurrent disease. Phase III assessment of carboplatin plus paclitaxel is warranted, alone or in combination with novel targeted therapies. Novel agents that target the epidermal growth factor receptor have shown particular promise in the management of squamous cell carcinoma of the head and neck.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Treatment Resistant Cancers

